Hydrogen (H2) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways

Yaxing Zhang1, Jingting Xu2, Zhiyuan Long1

  • 1Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University Guangzhou, China.

Frontiers in Pharmacology
|November 12, 2016
PubMed

Insights

Hydrogen (H2) administration prevents isoproterenol-induced cardiac hypertrophy and improves heart function by reducing oxidative stress. This study demonstrates H2

Area of Science:

  • Cardiovascular Research
  • Oxidative Stress Biology
  • Molecular Cardiology

Background:

  • Hydrogen (H2) exhibits significant antioxidant properties, offering potential in preventing diseases linked to oxidative stress.
  • Cardiac hypertrophy, an enlargement of the heart, is often associated with increased oxidative stress and can lead to heart failure.

Purpose of the Study:

  • To investigate the pharmacodynamics of hydrogen (H2) in a preclinical model of isoproterenol (ISO)-induced cardiac hypertrophy.
  • To elucidate the protective mechanisms of H2 against ISO-induced cardiac and cardiomyocyte hypertrophy.

Main Methods:

  • Animal model: C57BL/6J mice subjected to isoproterenol (ISO) infusion with or without H2 treatment.
  • In vitro study: H9c2 cardiomyocytes exposed to ISO and H2-rich medium.
  • Assessment of cardiac function, hypertrophy markers, reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and key signaling pathways (ERK1/2, p38, JNK).

Main Results:

  • H2 administration significantly prevented cardiac hypertrophy and improved cardiac function in ISO-treated mice.
  • In vitro, H2-rich medium blocked ISO-induced cardiomyocyte hypertrophy.
  • H2 inhibited NADPH oxidase, reduced ROS accumulation, preserved MMP, and suppressed ROS-sensitive signaling pathways (ERK1/2, p38, JNK).

Conclusions:

  • Hydrogen (H2) effectively inhibits isoproterenol-induced cardiac and cardiomyocyte hypertrophy both in vivo and in vitro.
  • H2 treatment improves impaired left ventricular function by partially blocking ROS-sensitive signaling pathways.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
20.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K